Nonmyeloablative Stem Cell Transplantation: Reduced-Intensity Conditioning for Cancer Immunotherapy - From Bench to Patient Bedside

Seminars in Oncology

Volumn 31, Issue 1, 2004, Pages 4-21

  Slavin, Shimon ^a   Morecki, Shoshana ^a   Weiss, Lola ^a   Shapira, Michael Y ^a   Resnick, Igor ^a   Or, Reuven ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTINEOPLASTIC AGENT; BUSULFAN; CLADRIBINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; GANCICLOVIR; IDARUBICIN; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CYTOMEGALOVIRUS INFECTION; DRUG TARGETING; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; LEUKEMIA; LUNG TOXICITY; LYMPHOCYTE; LYMPHOCYTE FUNCTION; LYMPHOMA; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 1142274325     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.10.016     Document Type: Article

References (95)

1. Sinkovics JG, Shullenberger CC, Howe CD: Prolongation and prevention of Rauscher virus mouse leukemia by spleen cells of naturally resistant or actively immunized mice. Clin Res 13:36-39, 1965
2. Boranic M, Tonkovic I: Time pattern of the antileukemia effect of graft-versus-host reaction in mice, I. Cellular events. Cancer Res 31:1140-1147, 1971
3. Weiden PL, Sullivan KM, Fluornoy N, et al.: Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304:1529-1533, 1981
4. Weiden PL, Fluornoy N, Sanders JE, et al.: Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation 13:248-251, 1981
5. Bortin MM, Truitt RL, Rimm AA, et al.: Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature 281:490-491, 1979
6. Slavin S, Weiss L, Morecki S, et al.: Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155-161, 1981
7. Truitt RL, Shih F-H, LeFever AV, et al.: Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol 131:2050-2058, 1983
8. Meredith RF, O'Kunewick JP: Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation 35:378-385, 1983
9. Moscovitch M, Slavin S: Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 132:997-1000, 1984
10. Slavin S, Strober S: Spontaneous murine B-cell leukemia. Nature 272:624-626, 1978
11. Slavin S, Weiss L, Morecki S, et al.: Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res 41:4162-4166, 1981
12. Vourka-Karussis U, Karussis D, Ackerstein A, et al.: Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 23:196-201, 1995
13. Moscovitch M, Slavin S: Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 132:997-1000, 1984
14. Morecki S, Moshel Y, Gelfend Y, et al.: Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer 71:59-63, 1997
15. Morecki S, Yacovlev E, Diab A, et al.: Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 58: 3891-3895, 1998
16. Morecki S, Yacovlev E, Gelfand Y, et al.: Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 24:114-121, 2001
17. Prigozhina T, Gurevitch O, Morecki S, et al.: Non-myeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in pre-clinical models. Exp Hematol 30:89-96, 2002
18. Slavin S, Weiss L, Morecki S, et al.: Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother 11:155-158, 1981
19. Slavin S, Fuks Z, Kaplan HS, et al.: Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med 147:963-972, 1978
20. Weiss L, Reich S, Slavin S: Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest 10:19-26, 1992
21. Weiss L, Reich S, Slavin S: Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant 6:229-233, 1990
22. Weiss L, Reich S, Slavin S: The role of antibodies to IL-2 receptor and anti-Asialo GMI antibodies on GVL effects induced by BMT in murine B cell leukemia. Bone Marrow Transplant 16:457-461, 1995
23. Weiss L, Reich S, Slavin S: Alloimmune-mediated GVL effects induced by unmodified and in vitro r-IL2 activated bone marrow and lymphocytes from different lymphoid compartments. Cytokines Cell Mol Ther 5:145-152, 1999
24. Slavin S, Ackerstein A, Kedar E, et al.: Induction of cell-mediated IL2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation. Transplant Proc 23:802-803, 1991
25. Ji YH, Weiss L, Zeira M, et al.: Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to up-regulate anti-tumor effects and down-regulate anti-host responses. Bone Marrow Transplant 32:495-504, 2003
26. Morecki S, Yacovlev E, Gelfand Y, et al.: Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 24:114-121, 2001
27. Slavin S, Ackerstein A, Weiss L: Adoptive immunotherapy in conjunction with bone marrow transplantation-Amplification of natural host defence mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Regul 7:180-184, 1988
28. Morecki S, Slavin S: Tumor dormancy induced by immune effector mechanisms in a murine model of B cell leukemia/lymphoma (BCL1), in Yafenof E, Scheuermann RH (eds): Premalignancy and Tumor Dormancy. New York, NY, Thomas, 1996, pp 137-146
29. Sullivan KM, Weiden PL, Storb R, et al.: Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720-1726, 1989
30. Ringden O, Horowitz MM: Graft-vs-leukemia reactions in humans. Transplant Proc 21:2989-2992, 1989
31. Horowitz M, Gale RP, Sondel PM, et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
32. Eibl B, Schwaighofer H, Nachbaur D, et al.: Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501-1508, 1996
33. Ben-Yosef R, Or R, Nagler A, et al.: Graft vs tumor and graft vs leukemia in patient with concurrent breast cancer and acute myelocytic leukemia. Lancet 348:1242-1243, 1996
34. Ueno NT, Rondón G, Mirza NQ, et al.: Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986-993, 1998
35. Or R, Ackerstein A, Nagler A, et al.: Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study. Cytokines Cell Mol Ther 4:1-6, 1998
36. Childs RW, Clave E, Tisdale J, et al.: Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 17:2044-2050, 1999
37. Childs R, Chernoff A, Contentin N, et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 11:750-758, 2000
38. Kapelushnik J, Or R, Aker M, et al.: Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant 19:96-98, 1996
39. Aker M, Kapelushnik J, Pugatsch T, et al.: Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta thalassemia major. J Pediatr Hematol Oncol 20:145-148, 1998
40. Slavin S, Nagler A, Naparstek E, et al.: Minitransplants and cell-based therapies for malignant and non-malignant disorders. Curr Opin Organ Transplant 4:184-188, 1999
41. Kolb HJ, Schattenberg A, Goldman JM, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050, 1995
42. Slavin S, Nagler A, Varadi G, et al.: Graft vs autoimmune lymphocytes (GVA) following allogeneic bone marrow transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 28:853-857, 2000
43. Slavin S, Nagler A, Varadi G, et al.: Graft vs autoimmune lymphocytes (GVA) following allogeneic bone marrow transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 28:853-857, 2000
44. Slavin S, Or R, Naparstek E, et al.: Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood 72:407a, 1988 (suppl 1, abstr)
45. Slavin S, Naparstek E, Or R, et al.: Prevention of GVHD and induction of graft vs leukemia (GVL) effects: Will it ever be possible? Bone Marrow Transplant 3:208-209, 1998 (suppl 1)
46. Slavin S, Ackerstein A, Nagler A, et al.: Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT). Blood 76:566a, 1990 (suppl 1, abstr)
47. Slavin S, Naparstek E, Nagler A, et al.: Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553-1562, 1995
48. Slavin S, Naparstek E, Nagler A, et al.: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 87:2195-2204, 1996
49. Naparstek E, Or R, Nagler A, et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br J Haematol 89:506-515, 1995
50. Naparstek E, Nagler A, Or R, et al.: Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies, in Cecka JM, Teraskaki PI (eds): Clinical Transplants. Los Angeles, CA, UCLA Tissue Typing Laboratory, 1996, pp 281-290
51. Bacigalupo A, Van Lint MT, Occhini D, et al.: Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77:1423-1428, 1991
52. Slavin S, Or R, Kapelushnik Y, Drakos P, et al.: Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 6:164-166, 1992
53. Kolb HJ, Mittermueller J, Clemm CH, et al.: Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76: 2462-2465, 1990
54. Goldman JM, Gale RP, Horowitz MM, et al.: Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806-814, 1988.
55. Bar BM, Schattenberg A, Mensink EJ, et al.: Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol 11:513-519, 1993
56. Leber B, Walker IR, Rodrigues A, et al.: Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation: Recovery complicated by initial pancytopenia and late dermatomyositis. Bone Marrow Transplant 12:405-407, 1993
57. Drobyski WR, Keever CA, Roth MS, et al.: Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318, 1993
58. Porter DL, Roth MS, McGarigle C, et al.: Induction of graft versus host disease for relapsed chronic myeloid leukemia. N Eng J Med 330:100-106, 1994
59. Mackinnon S, Papadopoulos EB, Carabassi MH, et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268, 1995
60. Papadopoulos EB, Ladanyi M, Emanual D, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho-proliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185-1191, 1994
61. Kolb H, Schattenberg A, Goldman J, et al.: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041-2050, 1995
62. Collins RH, Shpilberg O, Drobyski WR, et al.: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997
63. Kuzushima K, Yamamoto M, Kimura H, et al.: Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol 103:192-198, 1996
64. Gubbay I, Collignon J, Koopman P, et al.: A gene mapping to the sex-determining region of the mouse y chromosome is a member of a novel family of embryologically expressed genes. Nature 346:245-250, 1990
65. Pugatsch T, Oppenheim A, Slavin S: Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 17:273-275, 1996
66. Raanani P, Dazzi F, Sohal J, et al.: The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 99: 945-950, 1997
67. Johnson BD, Drobyski WR, Truitt RL: Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11:329-336, 1993
68. Kolb HJ, Mittermuller J, Gunther W, et al.: Adoptive immunotherapy in human and canine chimeras. Bone Marrow Transplant 12:561-564, 1993
69. Keating MJ, O'Brien S, McLaughlin P, et al.: Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther 38:S83-91, 1996 (suppl 2a)
70. Keating MJ, O'Brien S, Lerner S, et al.: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92: 1165-1171, 1998
71. Slavin S, Nagler A, Naparstek E, et al.: Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood 91:756-763, 1998
72. Khouri IF, Keating M, Korbling M, et al.: Transplantlite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16:2817-2824, 1998
73. Giralt S, Cohen A, Mehra R, et al.: Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 90:1853a, 1997 (suppl 1, abstr)
74. McSweeney PA, Wagner JL, Maloney DG, et al.: Out-patient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood 92:519a, 1998 (suppl 1, abstr 2133)
75. Carella AM, Giralt S, Slavin S: Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica 85:304-313, 2000
76. Carella AM, Champlin R, Slavin S, et al.: "Mini-allografts": Ongoing trials in humans. Bone Marrow Transplant 25:345-350, 2000
77. Kapelushnik J, Aker M, Pugatsch T, et al.: Bone marrow transplatation from a cadaveric donor. Bone Marrow Transplant 21:857-858, 1998
78. Nagler A, Ackerstein A, Kapelushnik J, et al.: Donor lymphocyte infusion post non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant 24:339-342, 1999
79. Kapelushnik J, Or R, Slavin S, et al.: Fludarabine based protocol for BMT in Fanconi anemia. Bone Marrow Transplant 29:1109-1110, 1997
80. Aker A, Varadi G, Slavin S, et al.: Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi's anemia. J Pediatr Hematol Oncol 21:237-239, 1999
81. Nagler A, Slavin S, Varadi G, et al.: Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for a malignant lymphoma. Bone Marrow Transplant 25:1021-1028, 2000
82. Slavin S, Nagler A, Varadi G, et al.: Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 28:853-857, 2000
83. Slavin S: Treatment of myeloid leukemias with non-myeloablative stem cell transplantation: Accomplishments and future goals. Educational Symposium, ASH, December 2000. Hematology 1:81-89, 2000
84. Nagler A, Aker M, Or R, et al.: Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 29:362-370, 2001
85. Giralt S, Gajewski J, Khouri I, et al.: Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia. Blood 90:1857a, 1997 (suppl 1, abstr)
86. Giralt S, Hester J, Huh Y, et al.: CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 86:4337-4343, 1995
87. Giralt S, Cohen A, Mehra R, et al.: Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenito cell transplantation in poor candidates for conventional myeloablative conditioning. Blood 90:1853a, 1997 (suppl 1, abstr)
88. Carella AM, Lerma E, Dejana A, et al.: Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica 83:904-909, 1998
89. Carella AM, Lerma E, Corsetti MT, et al.: Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Br J Haematol 103:565-567, 1998
90. Yu C, Storb R, Mathey B, et al.: DLA-identical bone marrow grafts after low-dose total body irradiation: Effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 86:4376-4381, 1995
91. Storb R, Yu C, Wagner JL, et al.: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 89:3048-3054, 1997
92. Storb R, Yu C, Barnett T, et al.: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given lymph node irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 90:1131-1136, 1999
93. Pelot MR, Pearson DA, Swenson K, et al.: Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant 5:133-143, 1999
94. Sykes M, Preffer F, McAfee S, et al.: Mixed lymphohematopoietic chimerism and graft-vs-lymphoma effects are achievable in adult recipients following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet 353:1755-1759, 1999
95. Morecki S, Yacovlev E, Gelfand Y, et al.: Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother 24:114-121, 2001